Sources of heterogeneity in case–control studies on associations between statins, ACE-inhibitors, and proton pump inhibitors and risk of pneumonia

European Journal of Epidemiology

Volumn 29, Issue 10, 2014, Pages 767-775

  de Groot, Mark C H ^a   Klungel, Olaf H ^a   Leufkens, Hubert G M ^a   van Dijk, Liset ^a,b   Grobbee, Diederick E ^c   van de Garde, Ewoudt M W ^a,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NETHERLANDS INSTITUTE FOR HEALTH SERVICES RESEARCH   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Ace inhibitors; Case control; Community acquired pneumonia; Epidemiology methods; Proton pump inhibitors; Statins

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CLINICAL PROTOCOL; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PREVALENCE; REFERENCE DATABASE; RISK ASSESSMENT; ADOLESCENT; AGED; CASE CONTROL STUDY; COMMUNITY-ACQUIRED INFECTIONS; EPIDEMIOLOGY; HEALTH SURVEY; NETHERLANDS; PNEUMONIA; RISK; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PNEUMONIA; POPULATION SURVEILLANCE; PROTON PUMP INHIBITORS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84911980935     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-014-9941-0     Document Type: Article

References (32)

1. Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, Gibson JE. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case–control study. Pharmacoepidemiol Drug Saf. 2009;18(4):269–75. doi:10.1002/pds.1715.
2. van de Garde EM, Endeman H, Deneer VH, et al. Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia. Chest. 2008;133(1):220–5.
3. Israili ZH, Hall WD. Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy: A Review of the Literature and Pathophysiology. Ann Intern Med. 1992;117(3):234–42. doi:10.7326/0003-4819-117-3-234.
4. Caldeira D, Alarcao J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012;345(jul11 1):e4260-e. doi:10.1136/bmj.e4260.
5. Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ. 2011;342:d1642. doi:10.1136/bmj.d1642.
6. Chopra V, Flanders SA. Statins and pneumonia. BMJ. 2011;342:d1907. doi:10.1136/bmj.d1907.
7. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310–9. doi:10.1503/cmaj.092129.
8. Lipchik RJ. Review: ACE inhibitors reduce risk for pneumonia. Ann Intern Med. 2012;157(10):JC5-2. doi:10.7326/0003-4819-157-10-201211200-02002.
9. Danaei G, Tavakkoli M, Hernan MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175(4):250–62. doi:10.1093/aje/kwr301.
10. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005;95(S1):S144–50. doi:10.2105/AJPH.2004.059204.
11. Stirbu-Wagner I, Dorsman SA, Visscher S et al. Landelijk Informatienetwerk Huisartsenzorg. Feiten en cijfers over huisartsenzorg in Netherlands. 2010. http://www.nivel.nl/representativiteit-van-linh. Accessed Sept 2012.
12. Klungel OH, Rietveld MC, de Groot MCH, et al. The Mondriaan Project: the Dutch health care landscape as a population laboratory. Value in Health. 2009;12(7):A392. doi:10.1016/s1098-3015(10)74933-0.
13. Remmelts HHF, Spoorenberg SMC, Oosterheert JJ, Bos WJ, de Groot MCH, van de Garde EMW. The role of vitamin D supplementation in the risk of developing pneumonia: three independent case–control studies. Thorax. 2013;68(11):990–6. doi:10.1136/thoraxjnl-2013-203623.
14. Grobbee DE, Hoes AW, Verheij TJ, Schrijvers AJ, van Ameijden EJ, Numans ME. The Utrecht Health Project: optimization of routine healthcare data for research. Eur J Epidemiol. 2005;20(3):285–7.
15. Fine MJ, Singer DE, Hanusa BH, Lave JR, Kapoor WN. Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital database. Am J Med. 1993;94(2):153–9.
16. Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9782):2023–30. doi:10.1016/S0140-6736(11)60607-7.
17. van de Garde EM, Endeman H, van Hemert RN, et al. Prior outpatient antibiotic use as predictor for microbial aetiology of community-acquired pneumonia: hospital-based study. Eur J Clin Pharmacol. 2008;64(4):405–10. doi:10.1007/s00228-007-0407-0.
18. Meijvis SC, Cornips MC, Voorn GP, et al. Microbial evaluation of proton-pump inhibitors and the risk of pneumonia. Eur Respir J. 2011;38(5):1165–72. doi:10.1183/09031936.00020811.
19. Almirall J, Bolíbar I, Serra-Prat M, et al. Inhaled drugs as risk factors for community-acquired pneumonia. Eur Respir J. 2010;36(5):1080–7. doi:10.1183/09031936.00022909.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. doi:10.1136/bmj.327.7414.557.
21. van Gageldonk-Lafeber AB, Bogaerts MA, Verheij RA, van der Sande MA. Time trends in primary-care morbidity, hospitalization and mortality due to pneumonia. Epidemiol Infect. 2009;137(10):1472–8. doi:10.1017/S0950268809002258.
22. Schouten JA, Prins JM, Bonten MJ, et al. Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia. Neth J Med. 2005;63(8):323–35.
23. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Angiotensin-converting enzyme inhibitor use and pneumonia risk in community-dwelling older adults: results from a population-based case–control study. Pharmacoepidemiol Drug Saf. 2012;21(11):1173–82. doi:10.1002/pds.3340.
24. van de Garde EMW, Deneer VH, Souverein PC, van den Bosch JM, Leufkens HGM. Validation of community-acquired pneumonia: high positive predictive value for ICD-9 codes. Pharmacoepidemiol Drug Saf. 2008;17:S248. doi:10.1002/pds.
25. Rafailidis PI, Matthaiou DK, Varbobitis I, Falagas ME. Use of ACE inhibitors and risk of community-acquired pneumonia: a review. Eur J Clin Pharmacol. 2008;64(6):565–73. doi:10.1007/s00228-008-0467-9.
26. Hu Z, Jin X, Kang Y, et al. Angiotensin-converting enzyme insertion/deletion polymorphism associated with acute respiratory distress syndrome among caucasians. J Int Med Res. 2010;38(2):415–22. doi:10.1177/147323001003800204.
27. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006;333(7576):999. doi:10.1136/bmj.38992.565972.7C.
28. Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21(3):383–8. doi:10.1097/EDE.0b013e3181d61eeb.
29. McCandless LC. Statin use and fracture risk: can we quantify the healthy-user effect? Epidemiology. 2013;24(5):743–52. doi:10.1097/EDE.0b013e31829eef0a.
30. Bavry AA, Bhatt DL. Interpreting observational studies—look before you leap. J Clin Epidemiol. 2006;59(8):763–4. doi:10.1016/j.jclinepi.2005.12.015.
31. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol. 2009;67(1):99–109. doi:10.1111/j.1365-2125.2008.03308.x.
32. Glynn RJ, Schneeweiss S, Wang PS, Levin R, Avorn J. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 2006;59(8):819–28. doi:10.1016/j.jclinepi.2005.12.012.